NCT07227753

Brief Summary

This study aims to examine whether naturally occurring bacteria in the gastrointestinal tract are associated with mood changes following childbirth, including postpartum depression. Biological samples will be collected before and after delivery to determine whether specific patterns in gut bacterial composition are linked to emotional states. The purpose of the research is to improve understanding of whether such microbial changes can help identify individuals at higher risk for postpartum depression, enabling earlier recognition and intervention.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Nov 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 10, 2025

Completed
3 days until next milestone

First Posted

Study publicly available on registry

November 13, 2025

Completed
4 days until next milestone

Study Start

First participant enrolled

November 17, 2025

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2026

Completed
Last Updated

January 15, 2026

Status Verified

November 1, 2025

Enrollment Period

6 months

First QC Date

November 10, 2025

Last Update Submit

January 14, 2026

Conditions

Keywords

depressionpostpartum

Outcome Measures

Primary Outcomes (1)

  • gut microbiota composition

    Compare gut microbiota composition between participants with postpartum depression (defined as Edinburgh Postnatal Depression Scale (EPDS; range 0-30; higher scores indicate more depressive symptoms) ≥13) and without postpartum depression (EPDS \<13).

    within 3 days before delivery; within 2 days after delivery

Secondary Outcomes (4)

  • Association between inflammatory cytokines and postpartum depressive symptom severity

    Within 3 days before delivery; within 2 days after delivery

  • Edinburgh Postnatal Depression Scale (EPDS; range 0-30; higher scores indicate more depressive symptoms)

    within 3days before delivery ; within 2 days after delivery; 6 weeks postpartum;

  • Changes in gut microbiota diversity (alpha and beta)

    within 3days before delivery ; within 2 days after delivery

  • Correlation between relative abundance of selected microbial taxa and maternal depressive symptom severity measured by the Edinburgh Postnatal Depression Scale (EPDS)

    within 3days before delivery ; within 2 days after delivery

Study Arms (2)

High-Edinburgh Postnatal Depression Scale cohort

Pregnant participants with antepartum Edinburgh Postnatal Depression Scale (EPDS; range 0-30; higher scores indicate more depressive symptoms) ≥13. Peripheral venous blood (serum) and rectal swab collected ≤3 days pre-delivery and ≤2 days postpartum; optional 6-week follow-up. Observational only-no interventions assigned.

Low-Edinburgh Postnatal Depression Scale cohort

Pregnant individuals with antepartum Edinburgh Postnatal Depression Scale (EPDS; range 0-30; higher scores indicate more depressive symptoms) \<13; same specimen collection and follow-up schedule as the high-EPDS cohort; no interventions assigned.

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsEligible participants are cisgender women who are pregnant or postpartum. Participants must have been assigned female at birth and currently self-identify as women.
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Women aged 18 years or older, with gestational age of at least 36 weeks, planning either vaginal or cesarean delivery. Individuals with serious digestive disorders, severe mental health conditions, or recent use of medications such as antibiotics or antidepressants that may affect gut bacteria are excluded.

You may qualify if:

  • Age 18 years or older
  • Gestational age at least 36 weeks, planned cesarean delivery
  • Ability to understand study procedures and provide informed consent
  • Voluntary agreement to participate in the study

You may not qualify if:

  • Gastrointestinal disorders or recent antibiotic use that significantly alters gut microbiome
  • Diagnosis of severe mental illness such as schizophrenia, schizoaffective disorder, bipolar disorder, or major depressive disorder with psychotic features
  • Medication use during pregnancy known to influence gut microbiota, including antidepressants, antibiotics, or fish oil
  • Refusal to provide rectal swab samples or inability to complete follow-up assessments

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Meikun Wang

Boston, Massachusetts, 02114, United States

RECRUITING

Related Publications (3)

  • Sun Y, Fan C, Lei D. Association between gut microbiota and postpartum depression: A bidirectional Mendelian randomization study. J Affect Disord. 2024 Oct 1;362:615-622. doi: 10.1016/j.jad.2024.07.057. Epub 2024 Jul 17.

    PMID: 39029663BACKGROUND
  • Jin W, Li B, Wang L, Zhu L, Chai S, Hou R. The causal association between gut microbiota and postpartum depression: a two-sample Mendelian randomization study. Front Microbiol. 2024 Sep 2;15:1415237. doi: 10.3389/fmicb.2024.1415237. eCollection 2024.

    PMID: 39286351BACKGROUND
  • Zhang Y, Baldyga K, Dong Y, Song W, Villanueva M, Deng H, Mueller A, Houle TT, Marcantonio ER, Xie Z. The association between gut microbiota and postoperative delirium in patients. Transl Psychiatry. 2023 May 9;13(1):156. doi: 10.1038/s41398-023-02450-1.

    PMID: 37160886BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Peripheral venous blood (\~5 mL; processed to serum and plasma) and rectal swab specimens will be collected around the time of delivery (pre-delivery within 3 days and early postpartum within 2 days). Specimens will be coded, stored at -80 °C, and used for laboratory analyses approved by the Institutional Review Board. No direct identifiers accompany specimens. No human whole-genome sequencing is planned.

MeSH Terms

Conditions

Depression

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehavior

Central Study Contacts

Jingping Wang, MD PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor, Harvard Medical School

Study Record Dates

First Submitted

November 10, 2025

First Posted

November 13, 2025

Study Start

November 17, 2025

Primary Completion

May 1, 2026

Study Completion

May 1, 2026

Last Updated

January 15, 2026

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will not share

Individual participant data will not be shared. The dataset contains sensitive clinical information from pregnant and postpartum patients at a single institution.

Locations